Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells

Journal of Pharmacological Sciences

Volumn 108, Issue 1, 2008, Pages 79-88

  Suzuki, Sachiko ^a   Oguro, Ami ^a   Osada Oka, Mayuko ^b,c   Funae, Yoshihiko ^c   Imaoka, Susumu ^a  

^a KWANSEI GAKUIN UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytochrome P450; Dihydroxyeicosatrienoic acid (DHET); Epoxyeicosatrienoic acid (EET); Hypoxia inducible factor (HIF); Vascular endothelial growth factor (VEGF)

Indexed keywords

11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 5,6 EPOXY 8,11,14 ICOSATRIENOIC ACID; 8,9 EPOXYICOSATRIENOIC ACID; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; DRUG METABOLITE; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; ERYTHROPOIETIN; LUCIFERASE; METHYL ARACHIDONYL FLUOROPHOSPHONATE; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHONIC ACID DERIVATIVE; SULFAPHENAZOLE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ARTERY ENDOTHELIUM; ARTICLE; BLOOD VESSEL TONE; CELL HYPOXIA; CONTROLLED STUDY; DRUG METABOLISM; ENZYME REGULATION; GENE OVEREXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; UMBILICAL ARTERY;

EID: 52949145571     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08122FP     Document Type: Article

References (42)

1. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 1996;78:415-423.
2. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature. 1999;401:493-497.
3. Hoebel BG, Graier WF. 11,12-Epoxyeicosatrienoic acid stimulates tyrosine kinase activity in porcine aortic endothelial cells. Eur J Pharmacol. 1998;346:115-117.
4. Fleming I, Fisslthaler B, Michaelis UR, Kiss L, Popp R, Busse R. The coronary endothelium-derived hyperpolarizing factor (EDHF) stimulates multiple signalling pathways and proliferation in vascular cells. Pflugers Arch. 2001;442:511-518.
5. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;285:1276-1279.
6. Daikh BE, Lasker JM, Raucy JL, Koop DR. Regio- and stereo-selective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J Pharmacol Exp. Ther. 1994;271:1427-1433.
7. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem. 1996;271:3460-3468.
8. Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J, et al. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem. 1997;272:12551-12559.
9. Hillig T, Krustrup P, Fleming I, Osada T, Saltin B, Hellsten Y. Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans. J Physiol. 2003;546:307-314.
10. Chen JK, Falck JR, Reddy KM, Capdevila J, Harris RC. Epoxyeicosatrienoic acids and their sulfonimide derivatives stimulate tyrosine phosphorylation and induce mitogenesis in renal epithelial cells. J Biol Chem. 1998;273:29254-29261.
11. Michaelis UR, Fisslthaler B, Medhora M, Harder D, Fleming I, Busse R. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J. 2003;17:770-772.
12. Michaelis UR, Fisslthaler B, Barbosa-Sicard E, Falck JR, Fleming I, Busse R. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci. 2005;118:5489-5498.
13. Pozzi A, Macias-Perez I, Abair T, Wei S, Su Y, Zent R, et al. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6-and 8,9-EET) as potent in vivo angiogenic lipids. J Biol Chem. 2005;280:27138-27146.
14. Tsuzuki Y, Fukumura D, Oosthuyse B, Koike C, Carmeliet P, Jain RK. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha → hypoxia response element → VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. 2000;60:6248-6252.
15. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda). 2004;19:176-182.
16. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271-275.
17. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292: 464-468.
18. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468-472.
19. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 2001;12:363-369.
20. Mottet D, Dumont V, Deccache Y, Demazy C, Ninane N, Raes M, et al. Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J Biol Chem. 2003;278:31277-31285.
21. Zhou J, Schmid T, Frank R, Brune B. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. J Biol Chem. 2004;279: 13506-13513.
22. Blancher C, Moore JW, Robertson N, Harris AL. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res. 2001;61:7349-7355.
23. Skinner HD, Zheng JZ, Fang J, Agani F, Jiang BH. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem. 2004;279:45643-45651.
24. Ng PS, Imaoka S, Hiroi T, Osada M, Niwa T, Kamataki T, et al. Production of inhibitory polyclonal antibodies against cytochrome P450s. Drug Metab Pharmacokinet. 2003;18:163-172.
25. Zhang B, Cao H, Rao GN. Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-Akt signaling in 14,15- epoxyeicosatrienoic acid-induced angiogenesis. J Biol Chem. 2006;281:905-914.
26. Popp R, Brandes RP, Ott G, Busse R, Fleming I. Dynamic modulation of interendothelial gap junctional communication by 11,12-epoxyeicosatrienoic acid. Circ Res. 2002;90:800-806.
27. Osada-Oka M, Takahashi M, Akiba S, Sato T. Involvement of Ca2+-independent phospholipase A2 in the translocation of hypoxia-inducible factor-1alpha to the nucleus under hypoxic conditions. Eur J Pharmacol. 2006;549:58-62.
28. Fang X, Kaduce TL, Weintraub NL, Harmon S, Teesch LM, Morisseau C, et al. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem. 2001;276:14867-14874.
29. He JC, Lu TC, Fleet M, Sunamoto M, Husain M, Fang W, et al. Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway. J Am Soc Nephrol. 2007;18:93-102.
30. Imaoka S, Hashizume T, Funae Y. Localization of rat cytochrome P450 in various tissues and comparison of arachidonic acid metabolism by rat P450 with that by human P450 orthologs. Drug Metab Pharmacokinet. 2005;20:478-484.
31. Osada M, Imaoka S, Funae Y. Apigenin suppresses the expression of VEGF, an important factor for angiogenesis, in endothelial cells via degradation of HIF-1alpha protein. FEBS Lett. 2004;575:59-63.
32. Osada M, Imaoka S, Sugimoto T, Hiroi T, Funae Y. NADPH-cytochrome P-450 reductase in the plasma membrane modulates the activation of hypoxia-inducible factor 1. J Biol Chem. 2002;277:23367-23373.
33. Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y, et al. Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol. 1996;51:1041-1050.
34. Ayajiki K, Fujioka H, Toda N, Okada S, Minamiyama Y, Imaoka S, et al. Mediation of arachidonic acid metabolite(s) produced by endothelial cytochrome P-450 3A4 in monkey arterial relaxation. Hypertens Res. 2003;26:237-243.
35. Carroll MA, Balazy M, Margiotta P, Falck JR, McGiff JC. Renal vasodilator activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclooxygenase and release of prostaglandins. J Biol Chem. 1993;268:12260-12266.
36. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, et al. The antiinflammatory effect of laminar flow: the role of PPAR-gamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A. 2005;102:16747-16752.
37. Catella F, Lawson JA, Fitzgerald DJ, FitzGerald GA. Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. Proc Natl Acad Sci U S A. 1990;87:5893-5897.
38. Potente M, Michaelis UR, Fisslthaler B, Busse R, Fleming I. Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1. J Biol Chem. 2002;277:15671-15676.
39. Oltman CL, Weintraub NL, VanRollins M, Dellsperger KC. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res. 1998;83:932-939.
40. Hirt DL, Capdevila J, Falck JR, Breyer MD, Jacobson HR. Cytochrome P450 metabolites of arachidonic acid are potent inhibitors of vasopressin action on rabbit cortical collecting duct. J Clin Invest. 1989;84:1805-1812.
41. Chen JK, Capdevila J, Harris RC. Overexpression of C-terminal Src kinase blocks 14, 15-epoxyeicosatrienoic acid-induced tyrosine phosphorylation and mitogenesis. J Biol Chem. 2000; 275:13789-13792.
42. Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang BH. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J. 2005;19:342-353.